Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung...
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Non-small-cNon-small-cell carcinomas (NSCLC) represent 80-85% of the worldwide lung cancer cases, which are the leading cause of cancer-related death. Several clinical trials have indicated better survival rates in NSCLC patients...
Non-small-cNon-small-cell carcinomas (NSCLC) represent 80-85% of the worldwide lung cancer cases, which are the leading cause of cancer-related death. Several clinical trials have indicated better survival rates in NSCLC patients treated with immune checkpoint inhibitor (ICI) antibodies targeting PD-1/PD-L1 or CTLA4. However, since many patients display innate or acquired resistance to these therapies, there is a pressing need to discover methods to help them overcome the resistance. Founders of Pulmobiotics, a spin-off created as a result of an ERC PoC project, have shown their ability to engineer and produce a non-pathogenic strain of the mild human lung pathogen Mycoplasma pneumoniae (the MycoChassis), used to stimulate the immune system to promote T cell infiltration in the tumor. The developed MycoChassis also secretes different immunomodulators (IL2, IL12, and Flt3L) in a sustained and local manner directly to the lung tumor, overcoming their high systemic doses of toxicity in patients. Pulmobiotics has further optimized the MycoChassis to meet safety requirements, engineered a development candidate product (PB_LC) for lung cancer treatment, and developed analytical methods to analyse its replication and biodistribution in vivo, critical regulatory requirements. The specific objectives of this EIC Transition proposal are to establish processes for manufacturing, formulation, and inhalation delivery of the product that meet GMP standards; to do preclinical regulatory activities (including efficacy, safety, and pharmacokinetics/ pharmacodynamics), as well as to advance the market and business preparation for the commercial exploitation of the first product of the company, PB_LC. Achieving the project objectives will pave the way to take PB_LC into first-in-human clinical trials and license the product to reach the market. The use of PB_LC will positively impact the quality of life of NSCLC patients by increasing the efficiency of currently used immunotherapies.ver más
04-11-2024:
Doctorados industria...
Se ha cerrado la línea de ayuda pública: Formación de doctores y doctoras de las universidades del Sistema universitario de Galicia (SUG) en empresas y centros de innovación y tecnología para el organismo:
04-11-2024:
PERTE-AGRO2
Se ha cerrado la línea de ayuda pública: PERTE del sector agroalimentario
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.